Genmab and Johnson & Johnson 'love' partnership as some ponder takeover

LONDON (Reuters) - Genmab was Europe's second biggest biotech company, until its partner Johnson & Johnson bought Switzerland's Actelion for $30 billion this year and propelled the Danish antibody specialist to the top spot.